Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × 130-nm albumin-bound paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 174 Breast Neoplasms 99 Carcinoma, Non-Small-Cell Lung 83 Triple Negative Breast Neoplasms 59 Neoplasms 39 Neoplasm Metastasis 39 Lung Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 19 Colorectal Neoplasms 16 Adenocarcinoma 16 Stomach Neoplasms 15 Melanoma 14 Esophageal Squamous Cell Carcinoma 14 Ovarian Neoplasms 11 Head and Neck Neoplasms 10 Carcinoma, Pancreatic Ductal 10 Carcinoma 10 Parkinson Disease 4, Autosomal Dominant Lewy Body 9 Gallbladder Neoplasms 9 Fallopian Tube Neoplasms 9 Esophageal Neoplasms 9 Biliary Tract Neoplasms 9 Cholangiocarcinoma 8 Carcinoma, Squamous Cell 8 Sarcoma 7 Neoplasms by Site 7 Small Cell Lung Carcinoma 6 Pancreatic Diseases 6 Digestive System Neoplasms 6 Pancreatic Adenocarcinoma 5

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04876313 2022-04-06

NURE-Combo

IRCCS San Raffaele

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡